BDH Industries Share Price

BDH Industries Limited, with its corporate operations in Mumbai, functions as a pharmaceutical company engaged in the manufacture and sale of therapeutic formulations. The company was founded in 1935 and is headquartered in Mumbai, Maharashtra. BDH Industries provides a comprehensive range of pharmaceutical products, including analgesics, antacids, antibacterial, anticoagulants, anticonvulsants, bronchodilators, corticosteroids, and oncology tablets and injections. The company operates through two segments: Pharmaceuticals and Renewable Energy, and exports to over 30 countries in all major continents, rooted in the heritage of the Indian pharmaceutical industry.

BDH Industries share price on BSE signifies how market participants react to the company’s operational performance and the overall developments in the pharmaceutical sector. The company’s financial health depends on demand for its pharmaceutical formulations, export volumes, and the performance of its renewable energy segment. BDH Industries stock price is influenced by various factors such as earnings, fluctuations in pharmaceutical demand, regulatory changes in the drug manufacturing sector, and the company’s ability to maintain quality compliance. In the longer run, strategies such as expanding product portfolio, enhancing manufacturing capabilities, and deepening export relationships affect the stock market sentiments. All these factors need to be monitored closely to have an idea about the company’s stock price movements.

BDH Industries live share price provides real time information about the last price traded, bid and ask prices, and volume traded. These indicators represent market activity and liquidity, reflecting investor response to corporate announcements, economic conditions, and sector news. Constant monitoring of the BDH Industries live price helps in observing short term price volatility and shows how a stock moves relative to the broader pharmaceutical index. Furthermore, monitoring BDH Industries stock price movements helps investors understand real time market sentiment, price fluctuations, and trading behaviour. It allows them to evaluate short term performance, and respond to news, quarterly results, or sector trends that may influence the company’s valuation and overall investment outlook.

BDH Industries Limited Company Fundamentals

a. Company Background

BDH Industries Limited was founded in 1935 and is headquartered in Mumbai, India. The company is engaged in the manufacture and sale of therapeutic formulations covering a range of pharmaceuticals in India and Internationally. It operates through two segments: Pharmaceuticals and Renewable Energy segments. The company has COPP for over 500 products, including capsules, dry syrup, external liquid, galenical, general injection, ointments, sterile ointments, tablets and oncology products. Its operations are based in India, with a state-of-the-art manufacturing facility located in Mumbai spread over 42,500 square feet, WHO-GMP and ISO 9001:2015 accredited, while corporate functions are managed from its administrative offices in Mumbai, Maharashtra. Over time, the company has built a reputation for manufacturing high quality, reliable and stable products. Financial performance is assessed through standard metrics such as revenue growth, operating margins, and return on equity. Market valuation indicators such as the P/E ratio are used by analysts for comparative assessment within the pharmaceutical sector. Overall fundamentals are influenced by pharmaceutical demand, raw material costs, and regulatory compliance requirements.

b. Company Product Lines

• Pharmaceutical Formulations

• Provides analgesics/antipyretic, analgesic balm, antacids, anthelmintics, antiprotozoal, anti-glaucoma, antiseptics, anti-psychotics, anti-tuberculosis, anti-allergic, anti-tussive, anti-asthmatics, antibacterial, antiseptic, anticancer, anticoagulants, anticonvulsants, antidiabetics, anti-emetics, antifungal, antigout, antimalarial, antiparkinsonisms, antispasmodics, and antiulcer

• Offers antivirals, sedatives/anxiolytics/antidepressants, calcium supplements, cardiovascular products, carminatives/aromatics, corticosteroids, diuretics, drugs acting on uterus, electrolyte replenishers, expectorants, iron supplements, laxatives, local anesthetics, general anesthetics, mydriatics, narcotic-analgesics, non-steroidal anti-inflammatory products, rubefacient and mild analgesics, and pharmaceutical aid products

• Supplies skin protectives, skin smootheners, and vitamins

• Provides SOULFIL, an oral pill for the treatment of erectile dysfunction in men

• Has a dedicated oncology division with separate facility for manufacturing oncology products

• Renewable Energy

• Operates two wind turbines with a total capacity of 0.8 MW located at Jaisalmer, Rajasthan

The product portfolio is structured to serve both domestic and international clients across the pharmaceutical industry.

c. Company Revenue Model

• Domestic Sales

• Revenue generated through the sale of pharmaceutical formulations to Indian clients

• Export Sales

• Contribution from international clients in over 30 countries

• Renewable Energy

• Income from wind turbine operations

Revenue performance is primarily influenced by pharmaceutical demand, export volumes, and pricing realizations in domestic and export markets.

d. Geographic Presence

• Corporate Headquarters

• Primary administrative and management functions based in Mumbai, Maharashtra, India

• Manufacturing Facilities

• Manufacturing facility located in Mumbai, spread over 42,500 square feet, WHO-GMP and ISO 9001:2015 accredited

• Renewable Energy Projects

• Two wind turbines with a total capacity of 0.8 MW located at Jaisalmer, Rajasthan

• Distribution Network

• Products exported to over 30 countries in all major continents

e. Key Milestones

• 1935 – Establishment: BDH Industries Limited was founded

• 1990 – Incorporation: The company was incorporated under the Companies Act, 1956

f. Industry Perspective

The pharmaceutical industry is capital intensive and closely linked to demand from healthcare and wellness sectors. Demand trends are influenced by economic activity, population growth, and changing healthcare needs. The industry is also affected by fluctuations in raw material costs, along with regulatory changes and quality compliance. Companies in the sector must manage regulatory compliance and supply chain efficiency while maintaining product quality. These factors collectively influence financial performance and investor perception of firms like BDH Industries.

BDH Industries Limited Stock Market Presence: Listings & Index Representation

BDH Industries Limited is listed on the Bombay Stock Exchange under the scrip code 524828. BDH Industries is actively traded on the BSE. The company’s market presence is within the small-cap segment of the market. Due to its size and sector focus, BDH Industries share price is generally tracked by investors interested in the pharmaceutical industry.

BDH Industries Limited is part of several broad-based and sector-specific stock market indices, reflecting its position as a small-cap pharmaceutical company in India. BDH Industries finds representation in these indices based on its market standing. This presence helps investors track the stock relative to other pharmaceutical companies. BDH Industries stock price is monitored by investors as a small-cap player in the Indian pharmaceutical sector. BDH Industries stock price is also tracked for its performance within the broader market context. BDH Industries provides insights into the small-cap segment of the pharmaceutical industry.

BDH Industries Limited Stock Performance and Share Price History

BDH Industries share price today on the BSE reflects its position as a small-cap pharmaceutical company in India. Its performance is qualitatively driven by factors such as demand for pharmaceutical formulations, export volumes, management of raw material costs, and the ability to maintain regulatory compliance. Investors compare BDH Industries movement with other pharmaceutical companies to assess relative strength. These underlying factors become visible through real market movements across different time periods. Similar trends appear during earnings driven price changes. Broader sector strength has also supported BDH Industries at certain times.

Beyond operational and sector influences, corporate actions such as the company’s strategic focus on expanding its product portfolio and maintaining quality compliance can significantly affect share price movements by shaping future growth expectations. This shows how strategic initiatives may trigger short term swings, even within a regulatory environment influenced by pharmaceutical demand cycles and client patterns. While short term movements respond to events and announcements, longer term valuation trends are better captured by BDH Industries annual high and low levels, offering context beyond daily or weekly changes. A notable peak indicates stronger pharmaceutical demand and stable margins, whereas a significant low aligns with market corrections or sector volatility. These extremes reflect the impact of economic conditions, raw material cost fluctuations, and earnings visibility, providing a framework for understanding historical performance. BDH Industries has a 52-week high of 523.75 and a 52-week low of 241.

BDH Industries behavior mirrors the trading patterns of a small-cap pharmaceutical company within India’s healthcare ecosystem. The company’s business portfolio spanning pharmaceutical formulations and renewable energy has shaped its price history. Over the past several years, BDH Industries has experienced periods of sharp gains followed by phases of consolidation. BDH Industries has shown volatility compared to larger pharmaceutical companies, reflecting the smaller scale of its operations. The company’s performance has closely tracked pharmaceutical demand and regulatory compliance cycles. Positive momentum appeared during periods of strong pharmaceutical demand and favourable regulatory conditions. However, periods of weak pharmaceutical demand and intensified competition have led to consolidation in BDH Industries

BDH Industries faced selling pressure when revenue growth showed signs of deceleration, reflecting structural shifts in how clients demand better quality with competitive pricing in the pharmaceutical market. Despite macroeconomic disruptions, BDH Industries showed resilience during certain recovery phases. While the broader pharmaceutical sector faced supply chain and regulatory challenges, the company’s diversified product portfolio and established manufacturing capabilities helped BDH Industries recover from certain lows. BDH Industries has declined for several recurring reasons. A drop in pharmaceutical demand or lower product realizations directly impacts revenue visibility and leads to selling pressure. Changes in government policy on pharmaceutical regulations or drug pricing can also cause BDH Industries share price to fall.

Moreover, increases in operational costs such as raw material prices without matching productivity gains squeeze margins, making BDH Industries less attractive. Periods of economic slowdown that affect healthcare spending raise concerns about order pipelines, leading to price declines. BDH Industries is sensitive to raw material cost movements. Broader market sell offs in small cap stocks also pull the price down, regardless of the company’s individual performance. Lower client retention or reduced order flow directly hurts revenue, resulting in a lower valuation. BDH Industries also faces pressure when clients demand better quality with competitive pricing, compressing revenue realization despite strong product momentum. BDH Industries share price has increased by 37.15% over the 52-week period.

BDH Industries share price has seen downward pressure when the company reported fluctuations in net profit margins. BDH Industries movements often mirror the broader pharmaceutical index trends. BDH Industries can be impacted by changes in pharmaceutical demand and raw material costs. BDH Industries has historically shown sensitivity to pharmaceutical regulations. BDH Industries may also be affected by the company’s ability to maintain its competitive edge in the pharmaceutical manufacturing space. BDH Industries performance is closely watched by investors tracking the small-cap pharmaceutical segment. BDH Industries stock price has moved within a 52-week range between 523.75 and 241. BDH Industries has seen fluctuations based on market conditions. BDH Industries stock price is influenced by various market factors.

BDH Industries Limited Investor Relevance and Role in Portfolio

BDH Industries Limited is a holding in small cap and pharmaceutical sector portfolios, offering exposure to therapeutic formulations, pharmaceutical manufacturing, and renewable energy. Its inclusion in major indices underscores its importance in India’s pharmaceutical space. The company’s position as a manufacturer of over 500 pharmaceutical products with WHO-GMP and ISO 9001:2015 accreditation, together with its export reach to over 30 countries and renewable energy operations, makes it a consideration for long term allocations. BDH Industries share price is influenced by the company’s ownership structure. BDH Industries’ equity is held by a broad mix of promoters, institutional investors, and retail investors, reflecting its standing in India’s pharmaceutical sector. The company’s management includes Jayashree G. Nair as Chairperson and Managing Director, and Suresh Chandra Kachhara as Joint MD, CFO and Executive Director. This investor base underscores the company’s role as a holding in portfolios concentrating on pharmaceuticals.

Beyond fundamentals and ownership, BDH Industries share price is actively monitored in the cash market segment, where trading volumes and delivery patterns reflect expectations on pharmaceutical demand, raw material costs, and regulatory policy actions. BDH Industries is available for trading on the BSE, allowing investors to take positions based on their outlook for the pharmaceutical sector. Market participants watch these trading indicators to gauge sentiment around quarterly results and policy announcements. BDH Industries share price is also evaluated for its volatility characteristics.

Technical indicators provide additional insight into short term momentum shifts in BDH Industries share price. While these indicators are primarily used for near term trading decisions, they also help investors and portfolio managers understand broader market sentiment and anticipate potential volatility, especially around key events or announcements. In the short term and weekly timeframe, the stock has exhibited price movements that correlate with broader pharmaceutical sector trends. Based on available data, the stock’s beta over 5 years monthly is 0.07, indicating lower volatility compared to the broader market. The company’s book value per share is a reference point for valuation. BDH Industries stock price is monitored by investors for its performance. BDH Industries share price is tracked for its movements.

Overall, BDH Industries demonstrates a lower volatility profile compared to the broader market, with the stock generally considered to have stable systematic risk. This makes it less sensitive to broader market movements compared to smaller pharmaceutical companies, though it remains exposed to sector specific factors such as pharmaceutical demand and raw material cost fluctuations. BDH Industries share price is also influenced by the company’s ability to manage operational efficiency and maintain its competitive position in the pharmaceutical manufacturing space.

BDH Industries Limited Sectoral Relevance and Peer Positioning

BDH Industries Limited sector relevance stems from its nine decade presence in the pharmaceutical industry, its position as a manufacturer of therapeutic formulations with WHO-GMP and ISO 9001:2015 accreditation, its portfolio covering analgesics, antacids, antibacterial, anticoagulants, anticonvulsants, bronchodilators, corticosteroids, oncology tablets and injections, its COPP for over 500 products, its export reach to over 30 countries, its renewable energy operations through two wind turbines with a total capacity of 0.8 MW, and its status as a publicly listed company since 1990. Peer comparisons with companies like Sun Pharmaceutical, Dr. Reddy’s Laboratories, Cipla, Lupin, and other pharmaceutical companies focus on revenue growth, margin performance, product portfolio diversity, and regulatory compliance rather than short term stock moves. These benchmarks help investors assess operational scale, efficiency, and regulatory adherence. Institutional tracking of pharmaceutical demand, raw material prices, and healthcare policies further highlights BDH Industries positioning within the broader Indian pharmaceutical market.

BDH Industries market cap highlights its position as a small cap player within the pharmaceutical sector. The company’s market capitalization has moved in line with investor perceptions of the company’s growth potential following its focus on expanding product portfolio and maintaining quality compliance. From earlier periods through more recent times, the market cap showed trends as the company expanded its product offerings and export reach. This pattern reflects investor confidence during favourable pharmaceutical cycles, followed by consolidation during challenging periods impacted by economic headwinds and structural shifts in the industry. The current market capitalisation of BDH Industries stands at Rs. 212.04 crore. This movement reflects the overall trend in BDH Industries share price.

BDH Industries earnings trajectory demonstrates the impact of its operational execution in a competitive industry. In recent fiscal years, total income showed trends supported by the core pharmaceutical business. The company operates through two segments: Pharmaceuticals and Renewable Energy. However, the company has faced headwinds from fluctuating raw material costs and intensified competition for market share.

BDH Industries EPS provides insight into its operational performance and income generation from pharmaceutical manufacturing activities. The company reported earnings that varied based on pharmaceutical cycles and demand patterns. The earnings per share has shown fluctuations over time, with basic EPS for recent periods reflecting the company’s performance. More recent performance suggests that EPS has shown certain trends as the company benefits from operational efficiency and market conditions.

BDH Industries P/E ratio reflects how investors perceive the company’s earnings relative to its revenue streams from pharmaceutical products. The current valuation compared to industry averages indicates how the market assesses the company’s earnings potential. The current P/E ratio is 19.16. The company’s profit after tax has varied across recent fiscal periods based on operational performance, with net profit showing certain trends. Overall, these changes highlight how market sentiment evolved alongside the company’s operational performance in a dynamic industry undergoing structural transformation. BDH Industries share price is monitored by investors tracking the pharmaceutical sector. BDH Industries share price is also evaluated for its performance relative to peers. BDH Industries share price is influenced by the company’s earnings and market conditions. BDH Industries share price is tracked for its movements in the small-cap segment.

Summary

BDH Industries Limited is a small-cap pharmaceutical company based in Mumbai, engaged in manufacturing therapeutic formulations with WHO-GMP accreditation and exporting to over 30 countries. The company’s performance is influenced by pharmaceutical demand, raw material costs, and regulatory policies. Investors track BDH Industries share price for insights into the small-cap pharmaceutical segment. BDH Industries stock price reflects the company’s operational performance and the broader economic environment.